Shorter infliximab infusion times without premedication do not increase adverse reactions
Journal of Pediatric Gastroenterology and Nutrition · 02.11.2026
DOI: 10.1002/jpn3.70642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 02.11.2026. Verfasst von Michael Lane und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Paediatric Gastroenterology, Children's Health Ireland, Dublin, Ireland. Die Arbeit nennt 39 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
Infliximab (IFX) infusions for paediatric inflammatory bowel disease (IBD) are resource intensive and time‐intrusive on patient's lives. Longer infusion times and administering routine pre‐medications compound such timelines, despite limited supporting evidence. This study investigated whether discontinuing routine premedication and shortening IFX infusion durations increased infusion reaction rates.
Methods
This retrospective comparative cohort study analysed data from 1083 IFX infusions (369 patients) at a single national referral centre. It compared a cohort receiving routine dual hydrocortisone/chlorphenamine premedication with longer infusion times (2.5 h induction/90 min maintenance; Group A) with a subsequent cohort without universal premedication and shorter infusions (2 h induction/60 min maintenance; Group B). The primary outcome was the rate of acute infusion reactions; secondary outcomes included anti‐IFX antibody formation and rates of post‐infusion reactions.
Results
There were 346 infusions in Group A and 737 infusions in Group B. Shorter infusions and omitting routine premedication did not increase acute infusion reaction rates (Group A: 1.5/100 vs. Group B: 1.1/100 infusions, p = 0.6; odds ratio 0.75 [0.24, 2.3]). Universal premedication neither reduced early anti‐IFX antibody positivity by first maintenance dose ( n = 51; 33% vs. 17%, p = 0.23) nor overall antibody prevalence (31% vs. 37%, p = 0.164). No reactions occurred during extended post‐infusion observation periods in either group.
Conclusions
Neither longer infusion times, universal pre‐medication nor prolonged post‐infusion observation significantly enhanced patient safety or reduced anti‐drug antibody formation. Practice modification could reduce treatment burden for patients and families and improve healthcare efficiency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Centre for Paediatric Gastroenterology, Children's Health Ireland, Dublin, Ireland.
- Pharmacy Department, Children's Health Ireland, Dublin, Ireland.
- Department of Paediatrics, School of Medicine, University College Dublin, Dublin, Ireland.
- Department of Paediatrics, Royal College of Surgeons Ireland, Dublin, Ireland.
- DOCHAS Study, Children's Health Ireland, Dublin, Ireland.
ORCID-Profile: Michael Lane, Séamus Hussey
Förderung
- None
Zitieren
APA
Lane, M., Almaiman, A., Obasi, S., Broderick, A., Bourke, B., Dunne, C., Fitzpatrick, E., Stenke, E., Stallard, L., Quinn, S., & Hussey, S. (2026). Shorter infliximab infusion times without premedication do not increase adverse reactions. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70642
Vancouver
Lane M, Almaiman A, Obasi S, Broderick A, Bourke B, Dunne C, et al. Shorter infliximab infusion times without premedication do not increase adverse reactions. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70642
BibTeX
@article{Lane2026,
author = {Lane, Michael and Almaiman, Ahmad and Obasi, Samuel and Broderick, Annemarie and Bourke, Billy and Dunne, Cara and Fitzpatrick, Emer and Stenke, Emily and Stallard, Lorraine and Quinn, Shoana and Hussey, Séamus},
title = {Shorter infliximab infusion times without premedication do not increase adverse reactions},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70642}
}
EUVIMED